Altria Releases Financial Report for Q4 2023 and Full Year, Net Revenue Reaching $24.48 Billion for 2023

Business by 2FIRSTS.ai
Feb.02.2024
Altria Releases Financial Report for Q4 2023 and Full Year, Net Revenue Reaching $24.48 Billion for 2023
Tobacco company Altschuyler reported a 2.2% decrease in Q4 and 2.4% decrease in full-year net revenues for 2023.

Altria Corporation, the official website, recently released its financial report for the fourth quarter and full year of 2023.

 

Altriai's net revenue in the fourth quarter of 2023 amounted to $5.98 billion, with a total net revenue of $24.48 billion for the entire fiscal year. This represents a decrease of 2.2% and 2.4% compared to the same period in 2022, respectively. The adjusted earnings per share for the fourth quarter remained unchanged at $1.18, as compared to the previous year.

 

According to a report released by ABC Company, the overall decline in net income was primarily attributed to a decrease in the revenue of the combustible tobacco products division. This decrease partially offset the increase in net income observed in the oral tobacco products division.

 

Ocheria expects its adjusted earnings per share for the full year of 2024 to be within the range of $5.00 to $5.15. This represents a growth rate of 1% to 4% compared to the baseline of $4.95 in 2023.

 

Billy Gifford, Chief Executive Officer of Orchia, has stated that electronic vaping products continue to be the most popular smoke-free products, with a growth of approximately 35% last year. However, a significant portion of this growth comes from illegally flavored disposable products, which account for half of the market share. Gifford stated, "The current state of the market is unacceptable for both legitimate manufacturers and consumers. These products are distributed by companies that have violated almost all regulations and guidelines issued by the US Food and Drug Administration since 2016.

 

Investors should take note that Altriai has enhanced shareholder returns through share buybacks and dividend payments.

 

In 2023, Ochiya repurchased 22.7 million shares at an average price of $43.96, returning $1 billion in cash to shareholders. The company's board of directors has now authorized a new $1 billion stock repurchase plan, expected to be completed by the end of 2024.

 

In August of last year, AAltria increased its dividend by 4.3%, marking the 58th dividend growth in the past 54 years. According to the financial report, dividends paid in the fourth quarter amounted to $1.7 billion, while dividends projected for 2023 are estimated at $6.8 billion.

 

In 2018, Altria acquired a 35% stake in e-cigarette company JUUL Labs for a total investment of $12.8 billion. However, the company faced legal challenges related to youth smoking as JUUL was accused of aggressively targeting the teenage market.

 

As of the end of 2022, Altria's valuation of JUUL has plummeted to only $250 million.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Alaska Settles with Juul and Altria for $7.8 Million After Five-Year Lawsuit
Alaska Settles with Juul and Altria for $7.8 Million After Five-Year Lawsuit
The State of Alaska has reached a $7.8 million settlement with e-cigarette maker Juul and its investor Altria, concluding a five-year lawsuit alleging the companies targeted Alaskan youth with nicotine products.
Dec.08 by 2FIRSTS.ai
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.
Oct.21
Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
This opinion piece, submitted by Samrat Chowdhery to 2Firsts, challenges the logic of tobacco price elasticity. It argues that high taxes often harm vulnerable populations and fuel illicit markets rather than reducing smoking.
Oct.21
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21
Product | HQD launches the new HQD GO in the U.S., featuring three power levels and a ~$30 price tag.
Product | HQD launches the new HQD GO in the U.S., featuring three power levels and a ~$30 price tag.
HQD has listed the disposable HQD GO on its official site and U.S. channels. The device touts 35,000 puffs, three power levels with adjustable airflow, and a 30 mg/ml nicotine strength. On U.S. retail websites, it’s priced at about $29.99.
Oct.24 by 2FIRSTS.ai
Philip Morris International Fails to Invalidate British American Tobacco Unit’s Vape Patent
Philip Morris International Fails to Invalidate British American Tobacco Unit’s Vape Patent
The European Patent Office’s Board of Appeal upheld British American Tobacco’s Nicoventures Trading Ltd. vape patent, rejecting Philip Morris International’s objections. The board ruled that the patent’s use of predefined heater activation parameters not based on user puffs was novel and valid.
Nov.10